目的 探究活血通脉片联合曲美他嗪治疗冠心病的临床效果。方法 选取2015年5月-2016年2月在临高县人民医院心内科进行治疗的冠心病患者60例，根据治疗方案的差别分成对照组与治疗组，每组各30例。所有患者均给予常规治疗。对照组口服盐酸曲美他嗪片，20 mg/次，3次/d。治疗组在对照组基础上口服活血通脉片，5片/次，3次/d。两组患者均连续治疗4周。观察两组的临床疗效，比较两组患者治疗前后血清炎性因子、血管内皮功能因子和心功能指标改善情况。结果 治疗后，对照组和治疗组总有效率分别为80.00%、96.67%，两组总有效率比较差异具有统计学意义（P<0.05）。治疗后，两组患者超敏C-反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）和丙二醛（MDA）水平较治疗前明显下降，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组上述血清炎性因子水平降低更明显，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者内皮素-1（ET-1）水平均较治疗前明显下降，NO、降钙素基因相关肽（CGRP）水平较治疗前明显升高，同组治疗前后比较差异具有统计学意义（P<0.05）；且治疗组这些观察指标的改善程度优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者左心室舒张末期内径（LVEDD）和左室后壁舒张期直径（LVPWd）明显降低，左心室射血分数（LVEF）指标升高，同组比较差异具有统计学意义（P<0.05）；且治疗组这些心功能指标改善程度优于对照组的，两组比较差异具有统计学意义（P<0.05）。结论 活血通脉片联合曲美他嗪治疗冠心病疗效显著，可明显改善患者心脏功能和血管内皮功能，降低炎性因子水平，具有一定的临床推广应用价值。

Objective To investigate the clinical curative effect of Huoxue Tongmai Tablets combined with trimetazidine in treatment of coronary heart disease. Methods Patients (60 cases) with coronary heart disease in Department of Cardiovascular Medicine of Lingao People's Hospital from May 2015 to February 2016 were divided into control and treatment groups according to different treatments, and each group had 30 cases. All patients in two groups were treated with the conventional therapy. Patients in the control group were po administered with Trimetazidine Dihydrochloride Tablets, 20 mg/time, three times daily. Patients in the treatment group were po administered with Huoxue Tongmai Tablets on the basis of the control group, 5 tablets/time, three times daily. The patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and the improvement of serum inflammatory factors levels, vascular endothelial functions, and cardiac function indexes before and after treatment in two groups was compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.00% and 96.67%, respectively, and there were differences between two groups (P<0.05). After treatment, hs-CRP, and TNF-α, and MDA levels in two groups were significantly decreased, and the differences were statistically significant in the same group (P<0.05). And these serum inflammatory factors levels in the treatment group were decreased more significantly than those in the control group, with significant difference between two groups (P<0.05). After treatment, ET-1 levels were significantly decreased, but NO and CGRP levels were increased, and the differences were statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, LVEDD and LVPWd in two groups were decreased, and LVEF index was increased, and there were differences in the same group (P<0.05). And these cardiac function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Huoxue Tongmai Tablets combined with trimetazidine has a good clinical curative effect in treatment of coronary heart disease, can significantly improve cardiac and endothelial functions with inflammatory factor levels reducing, which has a certain clinical application value.